Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling
- PMID: 26485620
- DOI: 10.1164/rccm.201505-1040OC
Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling
Abstract
Rationale: As of April 2015, participants in the Danish Lung Cancer Screening Trial had been followed for at least 5 years since their last screening.
Objectives: Mortality, causes of death, and lung cancer findings are reported to explore the effect of computed tomography (CT) screening.
Methods: A total of 4,104 participants aged 50-70 years at the time of inclusion and with a minimum 20 pack-years of smoking were randomized to have five annual low-dose CT scans (study group) or no screening (control group).
Measurements and main results: Follow-up information regarding date and cause of death, lung cancer diagnosis, cancer stage, and histology was obtained from national registries. No differences between the two groups in lung cancer mortality (hazard ratio, 1.03; 95% confidence interval, 0.66-1.6; P = 0.888) or all-cause mortality (hazard ratio, 1.02; 95% confidence interval, 0.82-1.27; P = 0.867) were observed. More cancers were found in the screening group than in the no-screening group (100 vs. 53, respectively; P < 0.001), particularly adenocarcinomas (58 vs. 18, respectively; P < 0.001). More early-stage cancers (stages I and II, 54 vs. 10, respectively; P < 0.001) and stage IIIa cancers (15 vs. 3, respectively; P = 0.009) were found in the screening group than in the control group. Stage IV cancers were nonsignificantly more frequent in the control group than in the screening group (32 vs. 23, respectively; P = 0.278). For the highest-stage cancers (T4N3M1, 21 vs. 8, respectively; P = 0.025), this difference was statistically significant, indicating an absolute stage shift. Older participants, those with chronic obstructive pulmonary disease, and those with more than 35 pack-years of smoking had a significantly increased risk of death due to lung cancer, with nonsignificantly fewer deaths in the screening group.
Conclusions: No statistically significant effects of CT screening on lung cancer mortality were found, but the results of post hoc high-risk subgroup analyses showed nonsignificant trends that seem to be in good agreement with the results of the National Lung Screening Trial. Clinical trial registered with www.clinicaltrials.gov (NCT00496977).
Keywords: chronic obstructive pulmonary disease; computed tomography; lung cancer; screening.
Comment in
-
Screening for Lung Cancer. Improving Outcomes with Better Patient Selection.Am J Respir Crit Care Med. 2016 Mar 1;193(5):478-9. doi: 10.1164/rccm.201510-2096ED. Am J Respir Crit Care Med. 2016. PMID: 26930429 No abstract available.
-
Personalized lung cancer screening: the value of spirometry and emphysema as risk modifiers.Ann Transl Med. 2016 Aug;4(15):293. doi: 10.21037/atm.2016.05.59. Ann Transl Med. 2016. PMID: 27569222 Free PMC article. No abstract available.
Similar articles
-
The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round.J Thorac Oncol. 2009 May;4(5):608-14. doi: 10.1097/JTO.0b013e3181a0d98f. J Thorac Oncol. 2009. PMID: 19357536 Clinical Trial.
-
Lung cancer histologies associated with emphysema on computed tomography.Lung Cancer. 2012 Apr;76(1):61-6. doi: 10.1016/j.lungcan.2011.09.003. Epub 2011 Sep 25. Lung Cancer. 2012. PMID: 21945657
-
Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.Lancet Oncol. 2016 Jul;17(7):907-916. doi: 10.1016/S1470-2045(16)30069-9. Epub 2016 Jun 6. Lancet Oncol. 2016. PMID: 27283862 Clinical Trial.
-
Can CT Screening Give Rise to a Beneficial Stage Shift in Lung Cancer Patients? Systematic Review and Meta-Analysis.PLoS One. 2016 Oct 13;11(10):e0164416. doi: 10.1371/journal.pone.0164416. eCollection 2016. PLoS One. 2016. PMID: 27736916 Free PMC article. Review.
-
CT screening for lung cancer: past and ongoing studies.Semin Thorac Cardiovasc Surg. 2005 Summer;17(2):99-106. doi: 10.1053/j.semtcvs.2005.05.002. Semin Thorac Cardiovasc Surg. 2005. PMID: 16087075 Review.
Cited by
-
Strengthening lung cancer screening in Europe: fostering participation, improving outcomes, and addressing health inequalities through collaborative initiatives in the SOLACE consortium.Insights Imaging. 2024 Oct 22;15(1):252. doi: 10.1186/s13244-024-01814-5. Insights Imaging. 2024. PMID: 39436577 Free PMC article.
-
Non-small-cell lung cancer.Nat Rev Dis Primers. 2024 Sep 26;10(1):71. doi: 10.1038/s41572-024-00551-9. Nat Rev Dis Primers. 2024. PMID: 39327441 Review.
-
Effects of low dose computed tomography (LDCT) on lung cancer screening on incidence and mortality in regions with high tuberculosis prevalence: A systematic review.PLoS One. 2024 Sep 11;19(9):e0308106. doi: 10.1371/journal.pone.0308106. eCollection 2024. PLoS One. 2024. PMID: 39259749 Free PMC article.
-
Clinical characteristics and prognosis of non-high-risk patients with incidental stage T1 lung cancer: A prospective cohort study.Clin Exp Med. 2024 Aug 21;24(1):195. doi: 10.1007/s10238-024-01459-0. Clin Exp Med. 2024. PMID: 39167309 Free PMC article.
-
Strong association between reduction of late-stage cancers and reduction of cancer-specific mortality in meta-regression of randomized screening trials across multiple cancer types.J Med Screen. 2024 Dec;31(4):211-222. doi: 10.1177/09691413241256744. Epub 2024 May 26. J Med Screen. 2024. PMID: 38797981 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
